OPTIMAL Motor Learning in Table Tennis: A fNIRS Study

October 27, 2026 updated by: Hui-Ting Shih, National Yang Ming Chiao Tung University

Does the OPTIMAL Theory Enhance Motor Learning and Cognitive and Sensorimotor Area Cortical Activation? A Theoretical Mechanism Validation in Young, Older Adults, and Cognitively Impaired Older Adults Novice Table Tennis Players

This study investigates how OPTIMAL theory influences table tennis backhand learning in young, healthy older, and mild cognitively impaired older adults. Meanwhile, we investigate the neural mechanisms of motor skill acquisition across different ages. This study utilizes functional near-infrared spectroscopy (fNIRS) to monitor brain activity. Beyond immediate performance, the research focuses on Retention (sustained skill over time) and Transfer (application to novel tasks) as critical indicators of true motor learning. To ensure objective results, a double-blind design is employed, where both participants and data analysts remain blinded to group assignments during behavioral and fNIRS data processing to minimize bias.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
90

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Taiwan
      • Taipei, Taiwan
        • National Yang Ming Chiao Tung University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Healthy young adults are aged between 18 and 30 years, while healthy older adults and older adults with mild cognitive impairment (MCI) are aged between 65 and 80 years. Regarding cognitive criteria, healthy young adults and healthy older adults must score 24 or higher on the Mini-Mental State Examination (MMSE). Older adults with MCI must further meet the following diagnostic criteria for MCI:

  1. Subjective cognitive decline: The participants themselves or their family members/primary caregivers report a decline in memory or cognitive function.
  2. Objective cognitive impairment: The education-adjusted score on the Taiwanese version of the Montreal Cognitive Assessment (MoCA-T) is between 20 and 23. One point is added to the total MoCA-T score for individuals with less than 12 years of education. Considering the heterogeneity in education levels among Taiwan's older generation, if a participant has 6 or fewer years of education (elementary school or below) or is illiterate, the Chinese version of the Montreal Cognitive Assessment Basic (MoCA-B) will be administered as a supplement. This is to reduce false-positive interference on the visuospatial and executive function subtests caused by a low educational level.
  3. Preserved activities of daily living: The score on the Compensatory Instrumental Activities of Daily Living (IADL-C) scale ranges from 1.34 to 3.06, indicating that the participant possesses the ability to live independently and has not reached the level of dementia.

In addition to the age and cognitive requirements, participants across all three groups must meet the following inclusion criteria:

  1. Right-handed, with an Edinburgh Handedness Inventory (EHI) score > 40;
  2. Table tennis beginners who have never received professional table tennis instruction;
  3. Played table tennis less than once a month in the past year;
  4. Normal hearing and normal or corrected-to-normal vision.

Exclusion criteria include:

  1. Over 3 years of experience in other racket sports;
  2. A history of neurological or psychiatric disorders;
  3. Any musculoskeletal system diseases that might interfere with the experiment;
  4. Unstable cardiopulmonary function rendering them unsuitable for moderate-intensity aerobic exercise;
  5. Taking medications that affect the central nervous system or blood oxygen signals, such as potent sedative-hypnotics, antiepileptic drugs, or antipsychotic medications.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Young Adults - OPTIMAL

OPTIMAL theory-based instruction
Behavioral: OPTIMAL theory-based Instruction

Dose: 15 blocks of practice, with each block consisting of 30 table tennis backhand strokes (Total: 450 trials).

Description: The intervention integrates three components: (1) Autonomy Support (AS): Participants choose the color of the table tennis balls. (2) Enhanced Expectancy (EE): A visual illusion is used where the target is surrounded by smaller circles, making the target appear larger to boost confidence. (3) External Focus (EF): Instructions direct attention toward the target rather than limb movements.
Active Comparator: Young Adults - Control

Conventional instruction
Behavioral: Conventional Instruction (Control)

Dose: Same as Experimental group (15 blocks x 30 trials; Total: 450 trials).

Description: (1) No choice is provided (Yoked control). (2) A visual illusion is used where the target is surrounded by larger circles, making the target appear smaller. (3) Instructions focus on body mechanics, such as elbow position and swing path (Internal Focus).
Experimental: Older Adults - OPTIMAL

OPTIMAL theory-based instruction
Behavioral: OPTIMAL theory-based Instruction

Dose: 15 blocks of practice, with each block consisting of 30 table tennis backhand strokes (Total: 450 trials).

Description: The intervention integrates three components: (1) Autonomy Support (AS): Participants choose the color of the table tennis balls. (2) Enhanced Expectancy (EE): A visual illusion is used where the target is surrounded by smaller circles, making the target appear larger to boost confidence. (3) External Focus (EF): Instructions direct attention toward the target rather than limb movements.
Active Comparator: Older Adults - Control

Conventional instruction
Behavioral: Conventional Instruction (Control)

Dose: Same as Experimental group (15 blocks x 30 trials; Total: 450 trials).

Description: (1) No choice is provided (Yoked control). (2) A visual illusion is used where the target is surrounded by larger circles, making the target appear smaller. (3) Instructions focus on body mechanics, such as elbow position and swing path (Internal Focus).
Experimental: MCI Older Adults - OPTIMAL

OPTIMAL theory-based instruction
Behavioral: OPTIMAL theory-based Instruction

Dose: 15 blocks of practice, with each block consisting of 30 table tennis backhand strokes (Total: 450 trials).

Description: The intervention integrates three components: (1) Autonomy Support (AS): Participants choose the color of the table tennis balls. (2) Enhanced Expectancy (EE): A visual illusion is used where the target is surrounded by smaller circles, making the target appear larger to boost confidence. (3) External Focus (EF): Instructions direct attention toward the target rather than limb movements.
Active Comparator: MCI Older Adults - Control

Conventional instruction
Behavioral: Conventional Instruction (Control)

Dose: Same as Experimental group (15 blocks x 30 trials; Total: 450 trials).

Description: (1) No choice is provided (Yoked control). (2) A visual illusion is used where the target is surrounded by larger circles, making the target appear smaller. (3) Instructions focus on body mechanics, such as elbow position and swing path (Internal Focus).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Motor Performance (Accuracy Score)
Time Frame: Day 1 Pre-test: before practice (3 blocks) Acquisition: during practice (15 blocks) Post-test: immediately after practice (3 blocks) Day 2 Retention test: at least 24 hours after Day 1 (3 blocks) Transfer test: at least 24 hours after Day 1 (3 blocks)

Accuracy is measured with a target-centered scoring system on a 0-7 scale per ball; higher scores indicate better accuracy.

7 pts: Hit target (10 cm diameter).

6 pts: Hit zone (20 cm).

5 pts: Hit zone (30 cm).

4 pts: Hit zone (40 cm).

3 pts: Hit zone (50 cm).

2 pts: Hit opposite table surface but missed target zones.

1 pt: Ball was hit but missed the opposite table.

0 pts: Failed to hit the ball.

The performance is presented by blocks. Each block contains 30 balls. The average score of each block is calculated.
Day 1 Pre-test: before practice (3 blocks) Acquisition: during practice (15 blocks) Post-test: immediately after practice (3 blocks) Day 2 Retention test: at least 24 hours after Day 1 (3 blocks) Transfer test: at least 24 hours after Day 1 (3 blocks)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Prefrontal Cortex (DLPFC) Activation
Time Frame: Day 1 Pre-test: before practice (3 blocks) Acquisition: during practice (15 blocks) Post-test: immediately after practice (3 blocks) Day 2 Retention test: at least 24 hours after Day 1 (3 blocks) Transfer test: at least 24 hours after Day 1 (3 blocks)

Change in oxygenated hemoglobin (HbO) concentration (μM) in the bilateral dorsolateral prefrontal cortex (DLPFC), measured using functional near-infrared spectroscopy (fNIRS) during table tennis backhand task blocks.
Day 1 Pre-test: before practice (3 blocks) Acquisition: during practice (15 blocks) Post-test: immediately after practice (3 blocks) Day 2 Retention test: at least 24 hours after Day 1 (3 blocks) Transfer test: at least 24 hours after Day 1 (3 blocks)
Premotor Cortex (PMC) Activation
Time Frame: Day 1 Pre-test: before practice (3 blocks) Acquisition: during practice (15 blocks) Post-test: immediately after practice (3 blocks) Day 2 Retention test: at least 24 hours after Day 1 (3 blocks) Transfer test: at least 24 hours after Day 1 (3 blocks)

Change in oxygenated hemoglobin (HbO) concentration (μM) in the bilateral premotor cortex (PMC), measured using functional near-infrared spectroscopy (fNIRS) during table tennis backhand task blocks.
Day 1 Pre-test: before practice (3 blocks) Acquisition: during practice (15 blocks) Post-test: immediately after practice (3 blocks) Day 2 Retention test: at least 24 hours after Day 1 (3 blocks) Transfer test: at least 24 hours after Day 1 (3 blocks)
Supplementary Motor Area (SMA) Activation
Time Frame: Day 1 Pre-test: before practice (3 blocks) Acquisition: during practice (15 blocks) Post-test: immediately after practice (3 blocks) Day 2 Retention test: at least 24 hours after Day 1 (3 blocks) Transfer test: at least 24 hours after Day 1 (3 blocks)

Change in oxygenated hemoglobin (HbO) concentration (μM) in the supplementary motor area (SMA), measured using functional near-infrared spectroscopy (fNIRS) during table tennis backhand task blocks.
Day 1 Pre-test: before practice (3 blocks) Acquisition: during practice (15 blocks) Post-test: immediately after practice (3 blocks) Day 2 Retention test: at least 24 hours after Day 1 (3 blocks) Transfer test: at least 24 hours after Day 1 (3 blocks)
Sensorimotor Cortex (SMC) Activation
Time Frame: Day 1 Pre-test: before practice (3 blocks) Acquisition: during practice (15 blocks) Post-test: immediately after practice (3 blocks) Day 2 Retention test: at least 24 hours after Day 1 (3 blocks) Transfer test: at least 24 hours after Day 1 (3 blocks)

Change in oxygenated hemoglobin (HbO) concentration (μM) in the sensorimotor cortex (SMC), measured using functional near-infrared spectroscopy (fNIRS) during table tennis backhand task blocks.
Day 1 Pre-test: before practice (3 blocks) Acquisition: during practice (15 blocks) Post-test: immediately after practice (3 blocks) Day 2 Retention test: at least 24 hours after Day 1 (3 blocks) Transfer test: at least 24 hours after Day 1 (3 blocks)
Self-Efficacy (General Self-Efficacy Scale, GSES)
Time Frame: Day 1 Immediately after Pre-test

Self-efficacy is measured with the General Self-Efficacy Scale (GSES), a 10-item self-report scale.

Each item is rated from 1 (not at all true) to 4 (exactly true), giving a total score of 10 to 40; higher scores indicate higher self-efficacy.
Day 1 Immediately after Pre-test

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Manipulation Check
Time Frame: Day 1 After Post-test Day 2 After Transfer test

A questionnaire verifying whether participants perceived the assigned experimental manipulations (autonomy support, enhanced expectancies, and attentional focus). It consists of 19 items rated mainly on 0-10 scales (items 10-11 on a 0-100% scale); higher scores indicate stronger agreement or greater perception of the corresponding construct.
Day 1 After Post-test Day 2 After Transfer test

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
National Yang Ming Chiao Tung University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 31, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 31, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 8, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 27, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 3, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 3, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 27, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NYCU115196AE

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings